Loading…
Loading…
EQUITY / NASDAQ · XNCM
Lakewood-Amedex Biotherapeutics, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.9326 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 0.9326 USD · Volume 120,517
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | Prior year | Change |
|---|---|---|---|
| Operating profit | -3,789,660 USD | — | — |
| Net income | -3,772,008 USD | — | — |
| Cash and cash equivalents | 2,584,774 USD | — | — |
| Total liabilities | 628,926 USD | — | — |
| Total equity | 4,331,083 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2026 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD | 2026 / Quarter 201/01/2025 – 06/30/2025ConsolidatedUnits · USD | 2026 / Quarter 201/01/2025 – 03/31/2025ConsolidatedUnits · USD | 2026 / Quarter 212/31/2024 – 12/31/2024ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 2,584,774 USD | — | — | 236,400 USD | — | — | — | — |
| Net incomeIncome statement | -3,772,008 USD | -4,695,299 USD | -923,291 USD | — | -655,943 USD | -1,195,560 USD | -539,617 USD | — |
| Operating profitIncome statement | -3,789,660 USD | -4,676,410 USD | — | — | -637,384 USD | -1,179,993 USD | — | — |
| Total assetsBalance sheet | 4,960,009 USD | — | — | 481,598 USD | — | — | — | — |
| Total equityBalance sheet | 4,331,083 USD | — | -2,841,648 USD | -1,964,537 USD | -683,251 USD | — | -76,233 USD | 409,611 USD |
| Total liabilitiesBalance sheet | 628,926 USD | — | — | 2,446,135 USD | — | — | — | — |
| Financing cash flowCash flow statement | — | 6,802,095 USD | — | — | — | 1,500,000 USD | — | — |
| Investing cash flowCash flow statement | — | -2,000,000 USD | — | — | — | — | — | — |
| Operating cash flowCash flow statement | — | -2,453,721 USD | — | — | — | -912,643 USD | — | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.